| Species |
Human |
| Protein Construction |
Integrin alpha V beta 8 (ITGAV & ITGB8) Heterodimer [Phe31-Val992 (ITGAV) acidic tail & Glu43-Arg684 (ITGB8) basic tail]
Accession # P06756-1 (ITGAV) & P26012-1 (ITGB8) |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human Latent TGF beta 1, His Tag at 5μg/ml (100μl/well) on the plate can bind Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer[Biotin], His & Avi, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
114 kDa (ITGAV)&76 kDa (ITGB8) kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 85-145 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Deletions of the genes encoding the integrin αVβ8 (Itgav, Itgb8) have been shown to result in abnormal vascular development in the CNS, including prenatal and perinatal hemorrhage. Other work has indicated that a major function of this integrin in vivo is to promote TGFβ activation. |
| Synonyms |
αVβ8; Integrin alpha V beta 8; TGAV&ITGB8;Integrin alpha V β 8 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
